A rare case report of gemcitabine-induced thrombotic microangiopathies [PDF]
SAGE Open Medical Case Reports, 2021 A 65-year-old female patient with breast cancer and soft tissue sarcoma who experienced a gemcitabine-induced thrombotic microangiopathies manifestation visited the emergency department.
Mohammed Ali Madkhali
doaj +2 more sources
Thrombotic microangiopathies: An illustrated review [PDF]
Research and Practice in Thrombosis and Haemostasis, 2022 The thrombotic microangiopathies (TMAs) are a heterogenous group of disorders with distinct pathophysiologies that cause occlusive microvascular or macrovascular thrombosis, and are characterized by microangiopathic hemolytic anemia, thrombocytopenia ...
Mouhamed Yazan Abou‐Ismail +4 more
doaj +2 more sources
Complement Mediated Endothelial Damage in Thrombotic Microangiopathies [PDF]
Frontiers in Medicine, 2022 Thrombotic microangiopathies (TMA) constitute a group of different disorders that have a common underlying mechanism: the endothelial damage. These disorders may exhibit different mechanisms of endothelial injury depending on the pathological trigger ...
Miquel Blasco +7 more
doaj +2 more sources
Ten tips for managing complement-mediated thrombotic microangiopathies (formerly atypical hemolytic uremic syndrome): narrative review [PDF]
BMC NephrologyComplement-mediated thrombotic microangiopathies (CM-TMA) are rare and life-threatening disorders characterized by microangiopathic hemolytic anemia, thrombocytopenia, and organ damage.
Pilar Musalem
doaj +2 more sources
HELLP Syndrome and Differential Diagnosis with Other Thrombotic Microangiopathies in Pregnancy [PDF]
DiagnosticsThrombotic microangiopathies (TMAs) comprise a distinct group of diseases with different manifestations that can occur in both pediatric and adult patients.
Stefano Raffaele Giannubilo +3 more
doaj +2 more sources
Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre [PDF]
BMC Nephrology, 2021 Background Gemcitabine is a broadly prescribed chemotherapy, the use of which can be limited by renal adverse events, including thrombotic microangiopathy (TMA). Methods This study evaluated the efficacy of eculizumab, a monoclonal antibody targeting the
Maximilien Grall +14 more
doaj +2 more sources
Pregnancy as a susceptible state for thrombotic microangiopathies [PDF]
Frontiers in MedicinePregnancy and the postpartum period represent phases of heightened vulnerability to thrombotic microangiopathies (TMAs), as evidenced by distinct patterns of pregnancy-specific TMAs (e.g., preeclampsia, HELLP syndrome), as well as a higher incidence of ...
Marie Frimat +5 more
doaj +2 more sources
Diagnostic Testing for Differential Diagnosis in Thrombotic Microangiopathies [PDF]
Turkish Journal of Hematology, 2019 Thrombotic microangiopathies (TMAs) are multiple disease entities with different etiopathogeneses, characterized by thrombocytopenia, microangiopathic hemolytic anemia (MAHA) with schistocytosis, variable symptoms including fever, and multi-organ failure
Gina Zini, Raimondo De Cristofar
doaj +2 more sources
Editorial: Thrombotic Microangiopathies, Diagnostic and Therapeutic Advances [PDF]
Frontiers in Medicine, 2021 Robert W. Maitta +3 more
doaj +2 more sources
Haematologica, 2022 Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is characterized by a severe ADAMTS13 deficiency due to the presence of anti-ADAMTS13 auto-antibodies, with subsequent accumulation of circulating ultra-large von Willebrand factor (VWF ...
Edwige Tellier +14 more
doaj +1 more source